An overview of obesity‐related complications: The epidemiological evidence linking body weight and other markers of obesity to adverse health outcomes
Open accessThe DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Abstract
Obesity is a highly prevalent chronic multisystem disease associated with shortened life expectancy due to a number of adverse health outcomes. Epidemiological data link body weight and parameters of central fat distribution to an increasing risk for type 2 diabetes, hypertension, fatty liver diseases, cardiovascular diseases including myocardial infarction, heart failure, atrial fibrillation, stroke, obstructive sleep apnoea, osteoarthritis, mental disorders and some types of cancer. However, the individual risk to develop cardiometabolic and other obesity‐related diseases cannot entirely be explained by increased fat mass. Rather than excess fat accumulation, dysfunction of adipose tissue may represent the mechanistic link between obesity and adverse health outcomes. There are people living with obesity who seem to be protected against the premature development of cardiometabolic diseases. On the other hand, people with normal weight may develop typical obesity diseases upon dysfunction of adipose tissue and predominantly visceral fat distribution. The mechanisms linking impaired function of adipose tissue in people with obesity include adipocyte hypertrophy, altered cellular composition, limited expandability of safe subcutaneous fat stores, ectopic fat deposition in visceral depots, the liver and other organs, hypoxia, a variety of stresses, inflammatory processes, and the release of pro‐inflammatory, diabetogenic and atherogenic signals. Genetic and environmental factors might contribute either alone or via interaction with intrinsic biological factors to variation in adipose tissue function. There are still many open questions regarding the mechanisms of how increased body weight causes obesity‐related disorders and whether these pathologies could be reversed. Evidence‐based weight loss interventions using behaviour change, pharmacological or surgical approaches have clarified the beneficial effects of realistic and sustained weight loss on obesity‐related complications as hard outcomes. This review focusses on recent advances in understanding epidemiological trends and mechanisms of obesity‐related diseases. Plain Language Summary: Obesity is a chronic complex and progressive disease characterized by excessive fat deposition that may impair health and quality of life. Worldwide, the number of adults living with obesity has more than doubled since 1990. Obesity may lead to reduced life expectancy, because it increases the risk for type 2 diabetes, cardiovascular diseases (e.g., myocardial infarction, high blood pressure, stroke), fatty liver diseases, musculoskeletal diseases, chronic respiratory diseases, depression and certain types of cancer. However, not every person with obesity develops these diseases. For better prevention and treatment, it is important to understand the mechanisms linking high fat mass to obesity related diseases. It has become clear that fat mass alone cannot explain the higher risk of obesity complications. People with obesity can have either high or low risk of developing complications. Compared to people with a low risk for obesity complications those with a high risk to develop obesity related diseases are characterized by higher central fat deposition in the abdominal region, on average bigger fat cells, higher number of immune cells in adipose tissue and altered signals released from adipose tissue that may directly affect the brain, liver, vasculature and other organs. Both inherited and environment factors may cause these abnormalities of adipose tissue function. However, weight loss through behaviour changes (e.g., lower calorie intake, higher physical activity), medications or obesity surgery can improve health, quality of life and reduce the risk for obesity related diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011 · cited 3×
“33 These risk reductions showed a sustained legacy effect even at the 15-year follow-up recall.”
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873 · cited 2×
“33,34 Interestingly, the required weight loss to prevent or delay type 2 diabetes in more than half of the study participants of the Diabetes Preventions Study and the Finnish Diabetes Prevention Study was only moderate (3% – 7%).”
The metabolic phenotype in obesity: Fat mass, body fat distribution, and adipose tissue function
Goossens, G. H. (2017) · Obesity Facts · doi:10.1159/000471488 · Cited by 8,481
Health effects of overweight and obesity in 195 countries over 25 years
Collaborators, T. G. 2. O. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614362 · Cited by 7,918
Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. Adults
Calle, E. E., Rodriguez, C., Walker-Thurmond, K., & Thun, M. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021423 · Cited by 7,696 · cited 2×
“81,82 Moreover, chronic subclinical inflammation in obesity, cellular stress upon nutrient excess, glucose and lipid toxicity and altered AT cross-talk may relate obesity to some cancer types (Figure 6).”
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Ong, K. L., Stafford, L. K., McLaughlin, S. A., Boyko, E. J., Vollset, S. E., Smith, A. E., Dalton, B. E., Duprey, J., Cruz, J. A., Hagins, H., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01301-6 · Cited by 6,146
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Obesity: global epidemiology and pathogenesis
Blüher, M. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0176-8 · Cited by 5,126
Self-citationTirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838 · cited 2×
“This effect is related to the extent of weight loss and has been shown for behaviour (LOOK AHEAD best responders 96 ), pharmacological (e.g., liraglutide, 97 dulaglutide, 98 semaglutide, 38 tirzepatide 99 ) and surgical interventions.”
Body-Mass Index and Mortality in a Prospective Cohort of U.S. Adults
Calle, E. E., Thun, M. J., Petrelli, J. M., Rodriguez, C., & Heath, C. W. (1999) · New England Journal of Medicine · doi:10.1056/nejm199910073411501 · Cited by 3,643
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236
Vrieze, A., Van Nood, E., Holleman, F., Salojärvi, J., Kootte, R. S., Bartelsman, J. F. W. M., Dallinga–Thie, G. M., Ackermans, M. T., Serlie, M. J., Oozeer, R., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.06.031 · Cited by 2,913
Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes
The Look AHEAD Research Group (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1212914 · Cited by 2,908
Yusuf, S., Hawken, S., Ôunpuu, S., Bautista, L., Franzosi, M. G., Commerford, P., Lang, C. C., Rumboldt, Z., Onen, C. L., Lisheng, L., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67663-5 · Cited by 2,903
Phelps, N. H., Singleton, R. K., Zhou, B., Heap, R. A., Mishra, A., Bennett, J. E., Paciorek, C. J., Lhoste, V. P., Carrillo-Larco, R. M., Stevens, G. A., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(23)02750-2 · Cited by 2,544 · cited 1×
“18,19 The ethnic differences in the development of obesity complications have been mainly attributed to differences between populations in body composition and fat distribution.”
General and abdominal adiposity and risk of death in Europe
Pischon, T., Boeing, H., Hoffmann, K., Bergmann, M., Schulze, M. B., Overvad, K., van der Schouw, Y. T., Spencer, E., Moons, K. G. M., Tjønneland, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801891 · Cited by 2,155 · cited 2×
“16 The link between obesity and increased cardiovascular disease risk might be causally mediated by genetic risk factors for adverse fat distribution as determined by the waist-to-hip ratio or insulin resistance in genome-wide association studies.”
Ashwell, M., Gunn, P., & Gibson, S. (2012) · Obesity Reviews · doi:10.1111/j.1467-789x.2011.00952.x · Cited by 2,130
Lean, M. E., Leslie, W. S., Barnes, A. C., Brosnahan, N., Thom, G., McCombie, L., Peters, C., Zhyzhneuskaya, S., Al-Mrabeh, A., Hollingsworth, K. G., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)33102-1 · Cited by 2,095
Garvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914 · cited 1×
“22 23 – 25 Within data from the National Health and Human Nutrition Examination Surveys (NHANES) 1988 – 1994, the Edmonton obesity staging system was a better predictor of mortality compared to obesity classes based on BMI categories even after adjustment for other measures of adiposity.”
Wing, R. R., Lang, W., Wadden, T. A., Safford, M., Knowler, W. C., Bertoni, A. G., Hill, J. O., Brancati, F. L., Peters, A., Wagenknecht, L., et al. (2011) · Diabetes Care · doi:10.2337/dc10-2415 · Cited by 1,828
Definition and diagnostic criteria of clinical obesity
Rubino, F., Cummings, D. E., Eckel, R. H., Cohen, R. V., Wilding, J. P. H., Brown, W. A., Stanford, F. C., Batterham, R. L., Farooqi, I. S., Farpour-Lambert, N. J., et al. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00316-4 · Cited by 1,811
Self-citationBariatric Surgery versus Conventional Medical Therapy for Type 2 Diabetes
Mingrone, G., Panunzi, S., De Gaetano, A., Guidone, C., Iaconelli, A., Leccesi, L., Nanni, G., Pomp, A., Castagneto, M., Ghirlanda, G., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200111 · Cited by 1,791 · cited 1×
“36 42 – 44 The examples from type 2 diabetes prevention and treatment trials suggest that the magnitude of weight loss and duration of the disease 45 represent important determinants of health benefits of weight loss interventions.”
Clinical Spectrum of Obesity and Mutations in the Melanocortin 4 Receptor Gene
Farooqi, I. S., Keogh, J. M., Yeo, G. S. H., Lank, E. J., Cheetham, T., & O'Rahilly, S. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022050 · Cited by 1,778
Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement
Neeland, I. J., Ross, R., Després, J.-P., Matsuzawa, Y., Yamashita, S., Shai, I., Seidell, J., Magni, P., Santos, R. D., Arsenault, B., et al. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30084-1 · Cited by 1,603
Blüher, M. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnaa004 · Cited by 1,090 · cited 3×
“2,46 – 50 A better stratification of obesity subphenotypes may help to prioritise treatment strategies and to identify those people who may benefit the most from weight loss interventions.”
Self-citationAdipokines in health and disease
Fasshauer, M., & Blüher, M. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.04.014 · Cited by 1,050
Self-citation(2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00291-0 · Cited by 1,029
Anti-obesity drug discovery: advances and challenges
Müller, T. D., Blüher, M., Tschöp, M. H., & DiMarchi, R. D. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00337-8 · Cited by 1,021 · cited 5×
“27,28,38,92,94,99,138 Moreover, the landscape of obesity complication management including MAFLD, heart failure, chronic kidney disease, obstructive sleep apnea and others will be changed by current and future incretin-based therapies.”
InfluentialSelf-citationTirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity
Packer, M., Zile, M. R., Kramer, C. M., Baum, S. J., Litwin, S. E., Menon, V., Ge, J., Weerakkody, G. J., Ou, Y., Bunck, M. C., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2410027 · Cited by 1,009
Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis
Loomba, R., Hartman, M. L., Lawitz, E. J., Vuppalanchi, R., Boursier, J., Bugianesi, E., Yoneda, M., Behling, C., Cummings, O. W., Tang, Y., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2401943 · Cited by 1,005
Weight and Metabolic Outcomes 12 Years after Gastric Bypass
Adams, T. D., Davidson, L. E., Litwin, S. E., Kim, J., Kolotkin, R. L., Nanjee, M. N., Gutierrez, J. M., Frogley, S. J., Ibele, A. R., Brinton, E. A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1700459 · Cited by 956
Why does obesity cause diabetes?
Klein, S., Gastaldelli, A., Yki-Järvinen, H., & Scherer, P. E. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2021.12.012 · Cited by 939
Absence of an Effect of Liposuction on Insulin Action and Risk Factors for Coronary Heart Disease
Klein, S., Fontana, L., Young, V. L., Coggan, A. R., Kilo, C., Patterson, B. W., & Mohammed, B. S. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033179 · Cited by 917
Tabák, A. G., Jokela, M., Akbaraly, T. N., Brunner, E. J., Kivimäki, M., & Witte, D. R. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60619-x · Cited by 898
Receptor-mediated activation of ceramidase activity initiates the pleiotropic actions of adiponectin
Holland, W. L., Miller, R. A., Wang, Z. V., Sun, K., Barth, B. M., Bui, H. H., Davis, K. E., Bikman, B. T., Halberg, N., Rutkowski, J. M., et al. (2011) · Nature Medicine · doi:10.1038/nm.2277 · Cited by 892 · cited 1×
“78 Taken together, altered cross-talk between AT and organs affected by obesity complications are candidates for future pharmacological treatment strategies.”
Klöting, N., Fasshauer, M., Dietrich, A., Kovacs, P., Schön, M. R., Kern, M., Stumvoll, M., & Blüher, M. (2010) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00586.2009 · Cited by 856 · cited 6×
“46,48 Predominantly gluteo-femoral fat accumulation — a phenotype more frequently observed in premenopausal women — is associated with lower triglyceride and higher HDL-cholesterol serum concentrations, improved insulin sensitivity, lower fasting blood glucose and insulin concentrations and…”
InfluentialSelf-citationle Roux, C. W., Astrup, A., Fujioka, K., Greenway, F., Lau, D. C. W., Van Gaal, L., Ortiz, R. V., Wilding, J. P. H., Skjøth, T. V., Manning, L. S., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30069-7 · Cited by 850
Self-citationGluteofemoral body fat as a determinant of metabolic health
Manolopoulos, K. N., Karpe, F., & Frayn, K. N. (2010) · International Journal of Obesity · doi:10.1038/ijo.2009.286 · Cited by 811
Sjöström, L., Gummesson, A., Sjöström, C. D., Narbro, K., Peltonen, M., Wedel, H., Bengtsson, C., Bouchard, C., Carlsson, B., Dahlgren, S., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70159-7 · Cited by 770
Sorli, C., Harashima, S.-I., Tsoukas, G. M., Unger, J., Karsbøl, J. D., Hansen, T., & Bain, S. C. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30013-x · Cited by 745
(2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)30162-0 · Cited by 738
A proposed clinical staging system for obesity
Sharma, A. M., & Kushner, R. F. (2009) · International Journal of Obesity · doi:10.1038/ijo.2009.2 · Cited by 687 · cited 1×
“22 23 – 25 Within data from the National Health and Human Nutrition Examination Surveys (NHANES) 1988 – 1994, the Edmonton obesity staging system was a better predictor of mortality compared to obesity classes based on BMI categories even after adjustment for other measures of adiposity.”
Douketis, J. D., Macie, C., Thabane, L., & Williamson, D. F. (2005) · International Journal of Obesity · doi:10.1038/sj.ijo.0802982 · Cited by 665 · cited 1×
“89,90 Therefore, many practice guidelines for the management of obesity adopted the ≥ 5% weight loss target.”
Caleyachetty, R., Thomas, G. N., Toulis, K. A., Mohammed, N., Gokhale, K. M., Balachandran, K., & Nirantharakumar, K. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.07.763 · Cited by 574 · cited 1×
“51 On the other hand, there are individuals with obesity that do not develop premature obesity-related cardiometabolic diseases.”
Past, present and future perspectives in nonalcoholic fatty liver disease
Sanyal, A. J. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0144-8 · Cited by 522 · cited 2×
“72 The prevalence of MAFLD has increased in parallel with the obesity pandemic and affects more than a fourth of the adult population in Western countries.”
Life expectancy after bariatric surgery in the Swedish obese subjects study
Carlsson, L. M. S., Sjöholm, K., Jacobson, P., Andersson-Assarsson, J. C., Svensson, P.-A., Taube, M., Carlsson, B., & Peltonen, M. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2002449 · Cited by 509 · cited 2×
“31 These benefits of bariatric surgery-induced weight loss were most likely attributable to long-term improvements in blood pressure, glucose and lipid metabolism.”
Neeland, I. J., Lim, S., Tchernof, A., Gastaldelli, A., Rangaswami, J., Ndumele, C. E., Powell-Wiley, T. M., & Després, J.-P. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00563-5 · Cited by 463
Tirzepatide for Obesity Treatment and Diabetes Prevention
Jastreboff, A. M., le Roux, C. W., Stefanski, A., Aronne, L. J., Halpern, B., Wharton, S., Wilding, J. P. H., Perreault, L., Zhang, S., Battula, R., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2410819 · Cited by 462 · cited 1×
“Whether weight loss strategies can reduce the incidence of obesity-related cancers needs to be systematically investigated in prospective studies.”
Ge, L., Sadeghirad, B., Ball, G. D. C., da Costa, B. R., Hitchcock, C. L., Svendrovski, A., Kiflen, R., Quadri, K., Kwon, H. Y., Karamouzian, M., et al. (2020) · BMJ · doi:10.1136/bmj.m696 · Cited by 426 · cited 1×
“108 According to a meta-analysis comparing dietary macronutrient patterns and dietary programmes for weight and CV risk factor reduction in overweight and obese adults, most dietary patterns resulted in similar, only modest short-term weight loss, but with substantial improvements in cardiovascular…”
Padwal, R. S., Pajewski, N. M., Allison, D. B., & Sharma, A. M. (2011) · Canadian Medical Association Journal · doi:10.1503/cmaj.110387 · Cited by 392
Butler, J., Shah, S. J., Petrie, M. C., Borlaug, B. A., Abildstrøm, S. Z., Davies, M. J., Hovingh, G. K., Kitzman, D. W., Møller, D. V., Verma, S., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)00469-0 · Cited by 386 · cited 1×
“111 In the SUMMIT trial, compared to placebo treatment with tirzepatide led to a 38% lower relative risk for an endpoint composed of death from cardiovascular causes or worsening of heart failure in patients with heart failure with preserved ejection fraction and obesity.”
Five-Year Outcomes of Gastric Bypass in Adolescents as Compared with Adults
Inge, T. H., Courcoulas, A. P., Jenkins, T. M., Michalsky, M. P., Brandt, M. L., Xanthakos, S. A., Dixon, J. B., Harmon, C. M., Chen, M. K., Xie, C., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1813909 · Cited by 381
Emdin, C. A., Khera, A. V., Natarajan, P., Klarin, D., Zekavat, S. M., Hsiao, A. J., & Kathiresan, S. (2017) · JAMA · doi:10.1001/jama.2016.21042 · Cited by 378
Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial
Ryan, D. H., Lingvay, I., Deanfield, J., Kahn, S. E., Barros, E., Burguera, B., Colhoun, H. M., Cercato, C., Dicker, D., Horn, D. B., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-02996-7 · Cited by 347
Obesity and cardiovascular disease: An ESC clinical consensus statement
Koskinas, K. C., Van Craenenbroeck, E. M., Antoniades, C., Blüher, M., Gorter, T. M., Hanssen, H., Marx, N., McDonagh, T. A., Mingrone, G., Rosengren, A., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae508 · Cited by 313 · cited 1×
“107 A nutritional energy deficit can be achieved by specific strategies including portion size control, reduction or elimination of ultra-processed foods such as sugar-sweetened beverages, reduction of alcohol consumption, and increased fruit and vegetable intake.”
Self-citationPerceptions of Barriers to Effective Obesity Care: Results from the National ACTION Study
Kaplan, L. M., Golden, A., Jinnett, K., Kolotkin, R. L., Kyle, T. K., Look, M., Nadglowski, J., O'Neil, P. M., Parry, T., Tomaszewski, K. J., et al. (2018) · Obesity · doi:10.1002/oby.22054 · Cited by 312
Ikramuddin, S., Korner, J., Lee, W.-J., Thomas, A. J., Connett, J. E., Bantle, J. P., Leslie, D. B., Wang, Q., Inabnet, W. B., Jeffery, R. W., et al. (2018) · JAMA · doi:10.1001/jama.2017.20813 · Cited by 291
Obesity and subtypes of incident cardiovascular disease
Ndumele, C. E., Matsushita, K., Lazo, M., Bello, N., Blumenthal, R. S., Gerstenblith, G., Nambi, V., Ballantyne, C. M., Solomon, S. D., Selvin, E., et al. (2016) · Journal of the American Heart Association · doi:10.1161/jaha.116.003921 · Cited by 259
Lotta, L. A., Wittemans, L. B. L., Zuber, V., Stewart, I. D., Sharp, S. J., Luan, J., Day, F. R., Li, C., Bowker, N., Cai, L., et al. (2018) · JAMA · doi:10.1001/jama.2018.19329 · Cited by 229
Stefan, N., & Schulze, M. B. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(23)00086-4 · Cited by 215
American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Hilliard, M. E., Johnson, E. L., Khunti, K., et al. (2024) · Diabetes Care · doi:10.2337/dc24-s008 · Cited by 213 · cited 2×
“The systematic evaluation of prospective observational studies provided data supporting a causal relationship between obesity and cancers of the oesophagus, colon and rectum, liver, gallbladder and biliary tract, pancreas, breast, uterus, ovary, kidney and thyroid.”
New insights into the treatment of obesity
Blüher, M., Aras, M., Aronne, L. J., Batterham, R. L., Giorgino, F., Ji, L., Pietiläinen, K. H., Schnell, O., Tonchevska, E., & Wilding, J. P. H. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15077 · Cited by 158
Self-citationSchmitz, J., Evers, N., Awazawa, M., Nicholls, H. T., Brönneke, H. S., Dietrich, A., Mauer, J., Blüher, M., & Brüning, J. C. (2016) · Molecular Metabolism · doi:10.1016/j.molmet.2015.12.001 · Cited by 148 · cited 1×
“53 Recently, two patterns of human unexplained phenotypic variation in obesity have been proposed by a multi-dimensional analysis of monozygotic phenotypically discordant twins.”
Self-citationButsch, W. S., Kushner, R. F., Alford, S., & Smolarz, B. G. (2020) · BMC Medical Education · doi:10.1186/s12909-020-1925-z · Cited by 145
Late Relapse of Diabetes After Bariatric Surgery: Not Rare, but Not a Failure
Aminian, A., Vidal, J., Salminen, P., Still, C. D., Nor Hanipah, Z., Sharma, G., Tu, C., Wood, G. C., Ibarzabal, A., Jimenez, A., et al. (2020) · Diabetes Care · doi:10.2337/dc19-1057 · Cited by 122
Horn, D. B., Almandoz, J. P., & Look, M. (2022) · Postgraduate Medicine · doi:10.1080/00325481.2022.2051366 · Cited by 114 · cited 3×
“75,83 There are still several obstacles to translate current knowledge about the causes of obesity and modern treatment options for people living with obesity.”
Qin, W., Yang, J., Deng, C., Ruan, Q., & Duan, K. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15386 · Cited by 72
Metadata
- Authors
- Blüher, M.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2025-03-11
- Volume
- 27
- Issue
- S2
- Pages
- 3-19
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W4408381871
- Cited by
- 175
- References
- 69
- FWCI
- 107.03
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.